Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Eisai reported global Leqembi sales of JPY 20.7 billion in Q4 2025, generating a SEK 127 million royalty payment to BioArctic — up ~31% year‑over‑year (approximately +50% at constant exchange rates) with stronger SEK noted as a material contributor to reported growth. Regulatory and commercialization progress continues to support upside: Leqembi is approved in 53 countries, was added to China’s NHSA commercial insurance list in December 2025, and a U.S. FDA Priority Review for the subcutaneous Leqembi Iqlik supplemental BLA has a PDUFA date of May 24, 2026. BioArctic and Eisai remain on track with upcoming earnings/disclosures (Eisai Feb 9; BioArctic full‑year report Feb 18) that could provide additional visibility on royalty trajectory and commercial rollout.

Analysis

Market Structure: Leqembi’s JPY 20.7bn Q4 sales and BioArctic’s SEK 127m royalty demonstrate accelerating commercial traction and durable cashflow for royalty holders; at constant FX BioArctic implied ~50% yoy royalty growth, signaling stronger-than-expected demand and pricing power for amyloid-targeting therapies in early AD across US/China/UK/Japan. Eisai/Biogen retain distribution leverage — winners are royalty holders (BIOA B) and integrated pharma (BIIB); losers are incumbents without disease-modifying AD assets and small developers reliant on partnering for commercialization.

Risk Assessment: Key tail risks are FDA setbacks (PDUFA May 24, 2026 on Iqlik subcutaneous start dose), ARIA/safety headlines, and rapid FX mean-reversion (SEK weakening would cut reported SEK royalties by ~30–50%). Near-term catalysts: Eisai Q3 FY2025 on Feb 9 and BioArctic FY report Feb 18; medium-term catalyst: May 24 PDUFA; long-term dependence on AHEAD/DIAN-TU readouts (multi-year). Hidden dependency: reimbursement rollout (US payer adoption) and China NHSA implementation timing.

Trade Implications: Tactical directional: favor BIOA B exposure to capture recurring royalties and upside from subcutaneous approval, but hedge FX and sector beta; use limited-risk call spreads on BIIB into May 24 to play positive regulatory cadence. Cross-asset: modest risk-off in biotech (XBI) would pressure purely developmental names — consider long BIOA B vs short XBI to isolate royalty upside.

Contrarian Angles: Consensus likely underweights FX-rebased earnings — SEK appreciation is an ephemeral boost that can reverse; market may underprice persistent royalty runway if subcutaneous Iqlik expands addressable market substantially (US convenience drives adherence). Overdone risk: a binary FDA/no-FDA reaction could create 30–50% vol dislocations; opportunistic buyers should scale into weakness after any knee-jerk selloff post-PDUFA if underlying royalty cadence remains intact.

Key Decisions for Investors

• Establish a 2–3% long position in BioArctic AB (Nasdaq Stockholm: BIOA B) before the FY2025 report on Feb 18, 2026 to capture royalty momentum; add another 1–2% if SEK-adjusted royalty growth >30% yoy or guidance is upgraded; initial stop-loss at -30%.
• Allocate 0.5–1% notional to a Biogen (BIIB) directional option trade: buy a Jun 2026 call spread (buy ATM-ish call, sell ~15% OTM call) sized to risk <=1% portfolio to play potential positive readthrough from the May 24, 2026 PDUFA; close within 5 trading days post-PDUFA or on 30% realized profit.
• Implement a pair trade to neutralize sector beta: go long BIOA B (2%) and short equivalent dollar exposure in XBI (ProShares S&P Biotech ETF) to isolate royalty-derived cashflow; rebalance after May 24 and unwind if divergence >25% or BIOA B SEK-adjusted guidance is cut.
• Hedge FX: if BIOA B position >1% of portfolio, hedge 50% of SEK exposure via USD/SEK forwards or buy SEK puts to limit reported-earnings volatility; unwind hedge if USD/SEK moves 5% in your favor or after two consecutive quarters of stable SEK.
• Cut risk immediately (reduce BIOA B and close BIIB option) if any regulatory safety communication on ARIA or an FDA denial occurs (binary event risk); if a selloff exceeds 30% absent negative fundamentals, scale into positions incrementally (25% increments) targeting average cost reduction.